bluebird bio's Zynteglo has become the first cell-based gene therapy to be approved in the US, getting the nod from the FDA as a treatment for patients with beta thalassaemia who require regular blood ...

Blue Bird Corporation is rated Buy, trading at a ~26% P/E discount to peers despite a strong margin profile and secular tailwinds. BLBD's revenue growth is supported by price hikes, backlog conversion ...

US cost-effectiveness watchdog ICER has handed bluebird bio some good news ahead of its FDA advisory committee meeting for rare blood disorder gene therapy beti-cel in June, by endorsing its proposed ...

Add Yahoo as a preferred source to see more of our stories on Google. Spring is here and there’s no other more beautiful bird to deliver the message than the Eastern Bluebird! April is the month in ...

At MP3Juices, we have everything you need to get your music fixed in one place. With a wide selection of tracks from popular artists and bands, we're sure you'll find what you're looking for. Explore ...

It might be my imagination, but all around the county, spring has already entered life ahead of the solstice marker. Oh, happy day. As the colors of trees, shrubs and flowers bring a gentle grace to ...

In this post, we have added some best free MP3 Tag Editor software for Windows 11/10 OS. If you have some MP3 files that contain empty or wrong metadata tags, then these tools can come in handy to ...

This page includes information about these cards, currently unavailable on NerdWallet. The information has been collected by NerdWallet and has not been provided or reviewed by the card issuer. Update ...

・ASTSpaceMobile expects to send satellites into orbit roughly every 45 days throughout 2026. ・BlueBird satellites use very large antenna arrays measuring nearly 2,400 square feet. ・AST SpaceMobile ...

TV and home video editor Ty Pendlebury joined CNET Australia in 2006, and moved to New York City to be a part of CNET in 2011. He tests, reviews and writes about the latest TVs and audio equipment.

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.